An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

Lilly

Status and phase: Completed; Phase 1

Conditions: Metastatic Colorectal Cancer

Treatments: Drug: Cetuximab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00207155

CA225-045

Details and patient eligibility

About

The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Measurable disease Tumor available for biopsies. Life expectancy of at least 3 months.

Exclusion criteria

• Known or documented brain metastases prior to Cetuximab therapy.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

110 participants in 1 patient group

A

Experimental group

Treatment:

Drug: Cetuximab